Issues surrounding genetic medicine and the Jewish population to be explored at conference

October 17, 1999

LOS ANGELES (Oct. 15, 1999) -- What if you learned you had a genetic susceptibility to cancer or another potentially life-threatening disease? Would you pursue a course of preventive treatment? What if your family members were at risk? Should they also be tested? Could you possibly face discrimination from employers or insurers?

These are just a few of the questions to be explored at "Genetic Medicine and the Jewish Population: Clinical, Ethical, Legal and Psychosocial Issues," a free community conference hosted for the first time by Cedars-Sinai Medical Center Oct. 24 in the Harvey Morse Auditorium. Registration starts at 8 a.m., and the conference and panel discussions begin at 9 a.m. and continue throughout the day. A complimentary kosher lunch will be served.

Continuing advances in genetic testing and medicine have opened the doors to important preventive strategies and, at the same time, raised issues related to how this knowledge may be used by health care consumers and the community at large.

"Over the last few years, we've seen much progress in the field of genetic research and prevention," said David L. Rimoin, M.D., Ph.D, Chair, Department of Pediatrics, and Director, Medical Genetics-Birth Defects Center, Cedars-Sinai Medical Center. "Some specific gene mutations are more common among people of Jewish ancestry, though no one population-Jewish or otherwise-has more mutations or genetic diseases. They're just distributed differently among different ethnic groups."

The purpose of the conference is to provide information on the historical, clinical, ethical, legal and social issues surrounding genetic medicine in the Jewish population. These issues will be addressed by experts in medicine, law and ethics as well as by individuals who have first-hand experience with these diseases. Audience members are encouraged to participate in the dialogue.

Conference presenters include Sen. Patrick Johnston, Chair, Senate Select Committee on Genetics and Public Policy; Michael M. Kaback, M.D., Professor of Pediatrics and Reproductive Medicine, University of California-San Diego and Children's Hospital and Health Center, San Diego; Robert J. Desnick, Ph.D., M.D., Professor and Chairman, Department of Human Genetics, Mount Sinai School of Medicine, New York University; and Lois Waldman, L.L.B., Co-Director, Commission on Law and Social Action and Urban Affairs, and Director, Women's Activities for the American Jewish Congress.

Participants from Cedars-Sinai include Dr. Rimoin; Rabbi Levi Meier, Ph.D.; Jerome Rotter, M.D., Co-Director, Medical Genetics-Birth Defects Center; Maren T. Scheuner, M.D., M.P.H., Director, GenRISK Program; Helen Hixon, M.S., C.G.C., Genetic Counselor, GenRISK Program; Rena Falk, M.D., Director, Prenatal Diagnosis Center; and Barry Rosenbloom, M.D., Director, Comprehensive Gaucher Treatment Center.

A dramatic example of the positive implications of genetic medicine, Dr. Rimoin pointed out, is the decreased incidence of Tay-Sachs disease in the Jewish population. In 1971, 80 Jewish children were born each year with the disease, compared to 12-15 non-Jewish children. Thanks to screening programs, the current incidence among Jewish children has dropped to two to three a year, while the rate among non-Jewish children has held steady.

"Tay-Sachs is literally not a Jewish disease anymore, though there is still a predisposition within this population," he stated. A Jewish Genetics Center, now in the planning stages at Cedars-Sinai, will provide comprehensive medical, psychosocial and educational services to enhance targeted health care delivery and lessen potential misuse of genetic information.

"Knowledge of Jewish heritage can focus and improve clinical care and disease prevention throughout an individual's lifetime," explained Dr. Scheuner, adding that the potential for misapplication of this information has led to concerns about stigmatization and discrimination.

"Knowledge is power," stated Dr. Scheuner. "This information can be put to good use. It may provide the basis for enhanced disease prevention strategies that may be life saving. Additionally, appropriate medical therapies targeted for a specific genetic risk may be recommended.

"Unfortunately, fears about misuse of this information may keep individuals from seeking information about their genetic susceptibilities. Fortunately, there is little evidence that such discrimination exists, and legislation is in place to protect us from such discrimination, though it may not be comprehensive enough."

One of the predominant issues surrounding genetic screening is determining when it is most appropriate and for whom, according to Dr. Falk. Because genetic screening is costly, it is more efficient-and cost-effective-to define five to eight potential conditions to screen for than to perform 50 random screenings.

"Every human being carries dangerous recessive genes that 'hide' while the dominant gene takes over," explained Dr. Falk. "We can't test everybody for everything, which leads to a number of important questions. At what point do we offer genetic testing? How significant must the risk be? What if the test is positive? What are the pros and cons of treatment?"

Dr. Falk hopes that the conference will draw community members and leaders as well as health care professionals, because a growing number of patients are seeking information on genetic medicine.

Sherman Oaks resident Marcia Litt was one of them. When she was diagnosed with breast cancer at age 48, Marcia was worried about more than her medical outcome. Her fears also focused on the possibility that her children-and other family members-could develop the same disease. Marcia had already seen two of her aunts succumb to breast cancer, and began to wonder if there might be a genetic susceptibility to the disease within her family.

"I gradually became proactive about educating myself about cancer," said Marcia, who underwent a lumpectomy, lymph node surgery, radiation and chemotherapy in 1997. Initially she was afraid to explore the subject for fear of learning more than she could handle emotionally. But with time that hesitation turned to action, as she began to seek information about the disease and, ultimately, decide to pursue genetic counseling and testing through Cedars-Sinai's GenRISK program. She credits that decision with saving her life . . . and possibly the lives of those she loves.

"The testing has really been helpful to me," said Marcia, who will share her experiences as part of the conference's consumer panel. "It's good preventative medicine, and I know how to take better care of myself now. Without the screening, I wouldn't be taking these proactive steps."

Another conference participant, Lenny Van Pelt, will discuss his experiences as both a patient coping with Gaucher disease and the founder of International Patient Advocacy Association (IPAA), a not-for-profit organization that provides legal resources and support to individuals with chronic illness and rare genetic disorders. Lenny was diagnosed with Gaucher disease in 1986, and has learned first-hand the struggles patients with such conditions face each day. Approximately one in 12 people of Ashkenazi ancestry carry the gene responsible for the disease, though Lenny is actually of pure Dutch descent.

"When I was diagnosed at 27, I had always thought of myself as a healthy individual and had never considered genetic issues related to my health," said Lenny, who is also an attorney. "One of my primary goals as a patient advocate is to increase education and awareness about genetic and chronic disease among health professionals as well as society as a whole."

Another important focus is bringing those most knowledgeable and concerned about these health conditions--researchers, physicians, patients, industry, nurses, counselors and other professionals-together under one umbrella to address patient needs.
For reservations or more information about the conference, call 1-800-CEDARS-1 (1-800-233-2771).

For media information and to arrange an interview, please e-mail or call 1-800-396-1002. Thanks for not including media contact information in stories.

Cedars-Sinai Medical Center

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to